Polio vaccination regimen shift to IPV followed by OPV instead of OPV alone debated at IoM/CDC conference.
• By The Pink Sheet
POLIO IMMUNIZATION WITH INACTIVATED AND LIVE VACCINES SHOULD REPLACE OPV, Samuel Katz, MD, Duke University, said at a June 8 Institute of Medicine/Centers for Disease Control & Prevention workshop on polio vaccines in Washington, D.C. In arguing for the change, Katz cited the estimated eight to 10 annual U.S. cases of vaccine-associated paralytic polio (VAPP) in people who have taken oral polio vaccine, and the three-year absence of the wild strain of polio from the Western hemisphere. "We have to show that we accept the fact that in a polio-free nation in a polio-free hemisphere we cannot have eight to 10 individuals paralyzed every year when there are alternatives," Katz said.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.